Wednesday broker round-up - UPDATE
28th Mar 2012 08:24
Babcock: UBS ups target from 800p to 880p, reiterates buy rating. Compass Group: Nomura keeps buy rating and 800p target. GKN: Investec reiterates buy rating and 240p target. Hansteen: Jefferies reiterates hold recommendation and 80p target. Henderson: Investec upgrades from hold to buy. Qineti
Read moreWednesday broker round-up - UPDATE
15th Feb 2012 09:25
Essar Energy: Morgan Stanley upgrades to neutral from underperform. Anglo American: Citi downgrades to neutral from buy. International Consolidated Airlines: Credit Suisse raises target from 152p to 189p, neutral rating kept. InterContinental Hotels: Credit Suisse raises target to 1,521p from 1,
Read moreTuesday newspaper round-up: Greece, Gas, Glenstrata
7th Feb 2012 06:54
Shoppers reverted to a bunker mentality over the new year, according to gloomy sales figures that quash any hope of consumers pulling the economy clear of a double-dip recession. Till receipts in January were 2.1% higher than a year ago, according to the British Retail Consortium. However, it said t
Read moreLondon close: Stocks finish up after US data
2nd Feb 2012 16:37
After a morning session in the red, UK stocks erased losses in afternoon trading after some better-than-expected data Stateside helped the outlook for the world's largest economy. Leading the rise on the Footsie were the miners after some M&A rumours bolstered gains. Nevertheless, analysts at Digi
Read moreFTSE 100 movers: Miners surge on Glencore-Xstrata merger speculation
2nd Feb 2012 14:46
Meanwhile, confirmation of a merger between Swiss commodities giants Glencore and Xstrata sent the two stocks to the top of the pile today, with Xstrata jumping 10% and Glencore rising 7%. A merger of mining outfit Xstrata and commodities trader Glencore could create a leviathan valued at around £52
Read moreSector movers: Smith & Nephew boosts health care stocks
2nd Feb 2012 14:11
The health care equipment and services sector was the best performer on Thursday afternoon after some well-received results from medical devices maker Smith & Nephew. The company saw revenue rise 3.66% to $1,106m in the final three months of 2011 from $1,067m in the corresponding quarter of last ye
Read moreLondon midday: Footsie flat despite mining strength, Xstrata surges
2nd Feb 2012 12:03
- Xstrata/Glencore surge on merger talks. - Mining strength outweighed by Astra, Unilever, Shell. - China considering increasing involvement in Eurozone rescue. The Footsie was broadly flat by lunchtime as poorly-received results from some big hitters outweighed strength in the mining sector. Mark
Read moreThursday broker round-up
2nd Feb 2012 09:15
AstraZeneca: Panmure Gordon maintains buy rating and 3,600p target. Imperial Tobacco: Nomura upgrades from reduce to neutral, 2,150p target unchanged. Compass Group: Panmure Gordon maintains buy rating and 675p target. Smith & Nephew: Panmure Gordon reiterates buy stance and 640p target. Unileve
Read moreLondon open: Stocks pull back but Xstrata soars
2nd Feb 2012 08:35
Stocks opened slightly lower on Thursday, pulling back from the +100 point gain for the Footsie yesterday as markets celebrated positive global macroeconomic data with manufacturing indices in the UK, Eurozone, US and China all showing an improvement in January. In other news, ratings agency Standa
Read moreLondon pre-open: Stocks to open slightly higher
2nd Feb 2012 07:45
City sources predict the FTSE 100 will open slightly higher, up 14 points from yesterday's close of 5,791, following strong gains in late trading on Wednesday. Fourth quarter sales at medical devices maker Smith and Nephew came in a touch shy of market expectations, but showed a modest improvemen
Read moreMargin recovers at Smith and Nephew
2nd Feb 2012 07:04
Trading profit margin recovered at Smith and Nephew in the fourth quarter as the medical devices maker boosted revenue and cut costs. Smith & Nephew (S&N) saw revenue rise 3.66% to $1,106m in the final three months of 2011 from $1,067m in the corresponding quarter of last year, a tad below market e
Read moreThursday preview: Shell, Unilever, Smith and Nephew
1st Feb 2012 15:29
As usual, Thursday is the busiest day of the week for scheduled company announcements and this week's big day looks busier than most, with big guns AstraZeneca, Royal Dutch Shell, Smith & Nephew and Unilever are all set to announce full-year results. Integrated oil giant Royal Dutch Shell is tipped
Read moreWednesday broker round-up - UPDATE
1st Feb 2012 07:03
Shire Pharmaceuticals: Credit Suisse maintains outperform rating and 2,350p target. Reckitt Benckiser: Credit Suisse maintains outperform rating and 3,800p target. easyJet: Credit Suisse maintains outperform rating and 503p target. Meggitt: Credit Suisse reiterates underperform rating and 330p ta
Read moreBroker snap: Nomura wary of rising competition for Smith & Nephew
27th Jan 2012 10:03
Nomura has maintained its neutral rating on medical devices marker Smith & Nephew (S&N) after assessing the read-across from US sector peers in the orthopaedic industry. This week, Zimmer, Stryker and Johnson & Johnson (J&J) have released their fourth quarter results, which were largely in line wit
Read moreFriday broker round-up - UPDATE
27th Jan 2012 09:43
CRH: Liberum Capital downgrades to hold from buy. Misys: Espirito Santo downgrades from buy to sell, cuts target to 263p from 275p. Aquarius: Credit Suisse maintains neutral and price target at £2.1. Lonmin: Credit Suisse maintains underperform and price target at £9.8. Imperial Tobacco: Cit
Read more